Akums Drugs (India) Investor Sentiment

AKUMS Stock   505.70  4.80  0.94%   
About 61% of Akums Drugs' investor base is looking to short. The analysis of the overall prospects from investing in Akums Drugs and suggests that many traders are, at the present time, alarmed. Akums Drugs' investing sentiment overview a quick insight into current market opportunities from investing in Akums Drugs and. Many technical investors use Akums Drugs stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
over a week ago at news.google.com         
Citi chooses this new debutant as top pick in midcap pharma space sees potential gains of 37 percent...
Google News at Macroaxis
over a month ago at news.google.com         
Akums Drugs slips 3 percent after posting 66 percent decline in Q3 profits, rev down 7 percent - Bus...
Google News at Macroaxis
over a month ago at news.google.com         
Akums Drugs shares fall nearly 6 percent following I-T Department search - Moneycontrol
Google News at Macroaxis
over a month ago at news.google.com         
Akums Drugs share price cracks 7 percent following IT Department search. Details here - Mint
Google News at Macroaxis
over two months ago at news.google.com         
Akums Drugs hits 10 percent upper circuit gains 12 percent in two days heres why - Business Standard
Google News at Macroaxis
over two months ago at news.google.com         
Akums Drugs bags 1,760 cr deal with European pharma stock jumps 5 - Fortune India
Google News at Macroaxis
over three months ago at news.google.com         
Akums Drugs shares hit second upper circuit, reach new high heres why - Business Standard
Google News at Macroaxis
over three months ago at news.google.com         
This drug maker falls 35 percent in 10 sessions to slip below its IPO price - CNBCTV18
Google News at Macroaxis
over three months ago at news.google.com         
Akums Drugs tanks 10, falls below issue price on weak Q2 earnings - Business Standard
Google News at Macroaxis
over three months ago at news.google.com         
API prices expected to stabilise by Q4FY25, says Akums Drugs Maheshwari Mint - Mint
Google News at Macroaxis
over three months ago at news.google.com         
Undiscovered Gems In India Akums Drugs and Pharmaceuticals And 2 Promising Small Caps - Yahoo Financ...
Google News at Macroaxis
over three months ago at news.google.com         
Akums Drugs Stocks Secures exclusive rights to Triple Hairs products in India - BusinessLine
Google News at Macroaxis
over three months ago at news.google.com         
Akums Drugs And Pharmaceuticals Share Price Today - Akums Drugs And Pharmaceuticals Stock Price Live...
Google News at Macroaxis
over six months ago at news.google.com         
Pharma stocks soar 6 percent as investors respond to double dose of Good News - Business Standard
Google News at Macroaxis
over six months ago at news.google.com         
Which stocks will be in focus today including Vedanta, Symphony, Akums Drugs and Tata Motors - Zee B...
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Akums Drugs that are available to investors today. That information is available publicly through Akums media outlets and privately through word of mouth or via Akums internal channels. However, regardless of the origin, that massive amount of Akums data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Akums Drugs news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Akums Drugs relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Akums Drugs' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Akums Drugs alpha.

Akums Drugs Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Akums Drugs hits 10 percent upper circuit gains 12 percent in two days heres why - Business Standard
12/27/2024
2
Citi chooses this new debutant as top pick in midcap pharma space sees potential gains of 37 percent - Zee Business
03/12/2025

Other Information on Investing in Akums Stock

Akums Drugs financial ratios help investors to determine whether Akums Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Akums with respect to the benefits of owning Akums Drugs security.